Oruka Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Selling, General & Admin	23.54	21.41	6.28	5.85	5.5	4.77
Research & Development	109.86	100.64	1.01	4.75	13.83	4.99
Total Operating Expenses	133.4	122.05	7.3	10.6	19.34	9.77
Operating Income	-133.4	-122.05	-7.3	-10.6	-19.34	-9.77
Interest Income	17.14	16.63	1.96	0.68	0.01	0.03
Interest Expense	-	-	-	-	-	-0.01
Other Non-Operating Income (Expense)	0	-0.01	-	-0.01	-	-
Total Non-Operating Income (Expense)	17.15	16.62	1.96	0.67	0.01	0.02
Pretax Income	-116.25	-105.43	-5.34	-9.93	-19.32	-9.75
Provision for Income Taxes	-	-	-	-	-	-0.01
Net Income	-116.25	-105.43	-5.34	-9.93	-19.32	-9.74
Net Income to Common	-116.25	-105.43	-5.34	-9.93	-19.32	-9.74
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	49	46	1	1	1	0
Shares Outstanding (Diluted)	49	46	1	1	1	0
Shares Change	2780.20%	3696.99%	0.04%	3.64%	195.18%	256.50%
EPS (Basic)	-1.94	-1.85	-4.44	-8.28	-16.68	-24.84
EPS (Diluted)	-1.94	-1.85	-4.44	-8.28	-16.68	-24.84
EPS Growth	-	-	-	-	-	-
Free Cash Flow	-91.19	-88.42	-5.01	-10.91	-18.81	-7.74
Free Cash Flow Growth	-	-	-	-	-	-
Free Cash Flow Per Share	-1.86	-1.94	-4.17	-9.09	-16.23	-19.73
EBITDA	-133.38	-121.97	-7.28	-10.58	-19.32	-9.76
EBIT	-133.4	-122.05	-7.3	-10.6	-19.34	-9.77
Effective Tax Rate	-	0.00%	0.00%	0.00%	0.00%	0.09%

SEC Filings: 10-K · 10-Q